GAG structure and function
GAGs are highly glycosylated and sulphated glycoproteins, consisting of dimeric repeated units containing an uronic acid (iduronic or glucuronic acid) and an aminosugar (glucosamine or galattosamine) [5] . These molecules are widely distributed in the body and prominent in extracellular matrices [5] .
Three major classes of GAGs have been described: a predominant large chondroitin sulphate, a small dermatan sulphate and a polydisperse heparan sulphate (HS) [5] . GAGs are vital in maintaining the structural integrity of the tissue and studies have shown that basement membranes contain HS in the form of a proteoglycan unique to that tissue [5] . HS forms anionic sites in this matrix and are thought to restrict the passage of proteins through the basement membrane [5] .
GAG metabolism and diabetes mellitus
In diabetic patients, the increased macromolecular permeability within the glomeruli that precedes the onset of established renal lesions and the increased vascular permeability to albumin seem to be related to structural alterations in the macromolecular pathway, i. e. the extracellular matrix, between the endothelial cells [4] . The nature of this alteration may be related to the loss of negatively charged molecules of extracellular matrix and of the endothelium, among which HS is highly represented. A number of reports indicate that HS metabolism is impaired in diabetes and this is responsible for the extracellular matrix negative charge loss [4] . HS is a strongly negatively charged molecule that is structurally similar to heparin but its base polymer has a lower degree of processing (sulphation, epimerization) (Fig. 1) . The HS chain imparts a negative charge to the basement membrane and determines the molecular charge permselectivity of the glomerular basement membrane [4] . The reduction in HS negative charges may depend on either a decreased sulphation of the glycosaminoglycan molecule or an absolute reduction Diabetologia (1998) 
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in the heparan sulphate-proteoglycan (HS-PG). It has been suggested that the first HS-PG change in diabetes might be an undersulphation of HS, followed by an absolute, or most likely a relative decrease in HS [6] .
Abnormal GAGs and diabetic nephropathy
The altered GAG metabolism in the diabetic kidney, and the abnormal GAG and extracellular matrix composition of the glomerular basement membrane may be important determinants of diabetic nephropathy, glomerulosclerosis, and renal failure due to the abnormal glomerular permselectivity to proteins and albuminuria. Data support the hypothesis that increased glomerular trafficking of proteins has detrimental effects on nephropathies, and in many primary glomerulopathies, proteinuria is certainly a risk factor for the development of glomerulosclerosis and renal failure [7] . However, the altered GAG or PG composition or both may be an important factor in the determination and the progression of diabetic nephropathy not only because of the abnormal glomerular basement membrane. The qualitative and quantitative changes in the PG composition of the renal extracellular matrix could also deeply affect the growth and synthetic behaviour of renal endothelial, mesangial, and glomerular and tubular epithelial cells, thus inducing glomerulosclerosis; indeed, the cell/extracellular matrix interaction plays an important role in regulating the adhesion, migration and proliferation of these cells [8] . Moreover, extracellular matrix and cell-associated PGs may modulate the activity of growth factors. In particular, it was suggested that the cell surface and extracellular matrix HS-PG may act together to regulate the bioavailability of otherwise diffusible effector molecules to their signal transducting receptor [8] . Note that a huge number of growth factors and cytokines are associated with HS-PGs and many are, or may be, involved in the pathogenesis of diabetic nephropathy [9] . Finally, it has recently been suggested that oxidative stress is involved in the pathogenesis of diabetic complications [10] . Further mesangial cells subjected to oxidative stress have been shown to selectively reduce HS synthesis [11] .
GAG treatment of diabetic nephropathy
The treatment of diabetic nephropathy with GAGs was originally proposed on the basis of the somewhat simple idea that restoring the lacking anionic charges and GAGs to the diabetic kidney could cure the albuminuria and putatively return the above described cell functional anomalies to normal [12] ( Fig. 2 ). The observation of pathophysiological similarities between diabetic nephropathy and the socalled ªremnant kidneyº, i. e. reduced functioning tissue after a renal lesion [13] , was also considered. In the classical model reproducing this kind of lesion, the 5/6 subtotal nephrectomized rat, heparin and derived drugs were shown to be effective in slowing down the progression to uraemia [14] . In view of these considerations, the effect of heparin and GAGs on diabetic nephropathy was studied in the streptozotocin diabetic model. This approach reduced glomerular basement membrane thickening [12] and anionic charge loss [12] , as well as mesangial area expansion [15] , and prevented the onset of albuminuria [12, 16] and the disorder in charge permselectivity [16] . Marshall et al. [15] , however, were not able to confirm a reduction of albumin excretion in female streptozotocin diabetic Wistar rats on a twice daily dose of 200 units heparin over a period of 6 months. They did, though, report that basement membrane thickness, mesangial volume fraction and absolute mesangial volume were lower in heparintreated diabetic animals compared with untreated diabetic animals [15] . Recently these discrepancies have been discussed extensively [17] . The difference in the results may be mainly due to different qualities and quantities of drugs in the different protocols [17] . Heparin and related drugs have no effect on the metabolic control of diabetes. GAGs have been demonstrated to modify the synthesis of PGs and other matrix proteins in vascular smooth muscle and endothelial cells by influencing extracellular matrix composition [18, 19] they could affect glomerular cell production of matrix/glomerular basement membrane constituents, and correct the diabetic extracellular matrix abnormalities responsible for glomerular basement membrane thickening and glomerulosclerosis. Indeed, in the streptozotocin model, heparin improved sulphate glomerular uptake, a metabolic marker of the endogenous GAG metabolism which is depressed in diabetes [16] and reduced collagen gene over-expression and the deposition of its protein [16] . In the streptozotocin model, heparin down-regulates collagen over-expression by interfering with the transforming growth factor (TGF)-b1 autocrine/paracrine loop, which is known to be activated in the diabetic kidney and is thought to play a very important role in the pathogenesis of this complication [9] . Low molecular weight dermatan sulphate, the GAG derivative that prevents the onset of diabetic renal alterations in the streptozotocin model [12] , also inhibits protein-kinase-C-dependent activation of the TGF-b1 gene in mesangial cells in vitro [20] .
In the light of these findings, studies were conducted in diabetic patients. Recent reports described favourable results on proteinuria in diabetic nephropathy following treatment with different GAGs. Treatment with a low molecular weight heparin reduced albuminuria in both micro-and macroalbuminuric Type I diabetic patients [21±22]. Danaparoid, a mixture of sulphated GAGs composed mainly of HS, also lowered proteinuria in a small double-blind, crossover study in Type I diabetic patients with albumin excretion rates higher than 300 mg/24 h [23] . A formulation composed of the two GAGs that were active in preventing diabetic nephropathy in the experimental model [12] was also tested in patients. Indeed, sulodexide, a GAG formulation composed of 80 % fast-moving heparin and 20 % dermatan sulphate, was reported to reduce albuminuria in Type I and Type II diabetic patients [24, 25] , and this effect lasted several weeks after its withdrawal [26] . This decrease in albuminuria was also documented in a cross-over study [27] and in patients to whom sulodexide was given orally [24, 27] .
GAGs, microalbuminuria, diabetic nephropathy and cardiovascular risk
As mentioned above, atherosclerosis is the main cause of death in diabetic patients and cardiovascular complications are frequently associated with diabetic nephropathy. It is noteable that the urinary excretion of albumin is significantly correlated with the incidence of mortality for cardiovascular events, in both Type I and Type II diabetic patients [3] . According to the ªSteno Hypothesisº, the increased risk of cardiovascular disease associated with nephropathy may be explained on the basis that HS metabolism in diabetes mellitus is not only altered within the glomerulus, but also within the capillary walls and the intima of large vessels [28] . Studies on muscle have demonstrated that the HS content of the basement membrane in muscle capillaries is reduced in diabetic patients with nephropathy and, noteably, is inversely correlated to the degree of albuminuria [29] . HS is also reduced in the intima of large vessels [30] .
The altered HS-PG metabolism in the vessel intima and luminal endothelial membrane may be a consequence of endothelial dysfunction in microalbuminuric diabetic patients. Reduced HS synthesis by endothelial cells might cause thrombophilia in diabetes mellitus because, due to its negative charge, HS regulates the development of pericellular thrombotic phenomena at the level of the endothelial membrane, by interacting with antithrombin III [31] . This hypothesis is supported by studies which found an increased ratio between fibrinogen and antithrombin III, due to a decrease in antithrombin III, in the aorta of diabetic rats [32] and the observation of increased levels of markers of thrombin activation in diabetic patients [33] . As recently suggested, this last condition may produce an increase in fibrinogen [34] , a well recognized cardiovascular risk factor also in diabetes [35] . The fall in endothelial cell HS contents might also influence local fibrinolysis. Endothelial cells synthesize specific HS and chondroitin sulphate to which tissue plasminogen activator (t-PA) can bind [36] . This t-PA binding capacity might be important in forming a t-PA storage pool, from which t-PA is released and made locally available under certain circumstances [36] . HSbound t-PA released from endothelial cells would provide an additional mechanism for locally increased fibrinolytic activity and render endothelial cells resistant to fibrin deposition. Thus, the derangement in this fibrinolytic mechanism could lead to increased fibrin deposition on the vascular wall in diabetes.
Perspectives
Although only small studies have been conducted, the favourable effects of GAG treatment on albuminuria in diabetic nephropathy are encouraging. Clearly, dose-finding and long-term studies are needed to demonstrate that these drugs are capable of curing human diabetic nephropathy and not simply albuminuria. Interest, however, in GAGs is increasing, since these molecules have shown a beneficial effect on diabetic retinopathy [37] . Moreover, these drugs might retard the natural development of diabetic macroangiopathy and thrombosis. Indeed, the existence of common features (i. e. abnormal permeability to albumin) and pathogenetic mechanisms (i. e. altered HS metabolism, extracellular matrix deposition, overactivity of growth factors loops) between diabetic nephropathy and diabetic macroangiopathy and the ability of GAGs to act favourably on specific disorders of the vessel wall and endothelium (i. e. those disorders which lead to thrombophilia) suggests the possibility that these drugs might also be effective in preventing or curing or both not only diabetic nephropathy, but also diabetic macroangiopathy.
An increasing number of studies are showing that the administration of GAGs lowers fibrinogen levels, the relevance of which as a cardiovascular risk factor in diabetes has already been stressed [35] . In particular, the fibrinogen reducing activity of sulodexide was demonstrated in hyperlipidaemic subjects [38] and in pilot studies in diabetic patients [25, 39] . GAGs are also effective in stimulating fibrinolysis, and sulodexide was shown to improve fibrinolysis in diabetic patients [40] . Finally, heparin-like GAGs may modulate the procoagulant properties of endothelial cells through the increase of HS at the endothelial membrane level [19] . That these GAG activities may have therapeutic relevance in cardiovascular disease is supported by the reduction in total mortality, reinfarction rate and mural thrombus formation observed in patients treated with sulodexide after acute myocardial infarction [41] .
Further studies of the structure-function relationship of heparin and GAGs and their optimal dosage may provide a unique opportunity to select new derivatives with specific effects on diabetic nephropathy and macroangiopathy, possibly and most importantly without anticoagulation. Such a prospect might be possible because some of the previously reported GAG effects depend on their non-sulphated molecular back-bone or are reached at non-anticoagulant dosages or both. Studies on the bioavailability of orally dispensed GAGs would also be very important. It has been demonstrated that after oral administration heparin and dermatan sulphate are absorbed [42±44] and, most importantly, maintain their effects not only on coagulation, but on albuminuria, as observed by Solini et al. [27] in diabetic patients treated with sulodexide.
